Status:
COMPLETED
Immunoadsorption, Dexamethasone Pulse Therapy and Rituximab for Pemphigus
Lead Sponsor:
University of Luebeck
Conditions:
Pemphigus
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
Pemphigus is a severe autoimmune blistering disease mediated by circulating antibodies against certain proteins important for maintaining skin integrity. Protein A immunoadsorption is a dialysis-like ...
Eligibility Criteria
Inclusion
- Diagnosis of pemphigus confirmed by immunofluorescence and desmoglein ELISA.
- Severe disease or past treatment(s) not effective or past treatment(s) not tolerated.
Exclusion
- General condition too poor to tolerate immunoadsorption treatment.
- Severe dementia or psychiatric disease.
Key Trial Info
Start Date :
January 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2011
Estimated Enrollment :
23 Patients enrolled
Trial Details
Trial ID
NCT00656656
Start Date
January 1 2008
End Date
July 1 2011
Last Update
March 13 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Dermatology, University of Luebeck
Lübeck, Schleswig-Holstein, Germany, 23552